Sec Form 13G Filing - GSA CAPITAL PARTNERS LLP filing for T2 BIOSYSTEMS INC PAR $0.0 (TTOO) - 2023-07-31

Securities and Exchange Commission, Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
(Amendment No.__)*
(Name of Issuer) : T2 Biosystems Ord
(Title of Class of Securities) : Common Stock
(CUSIP Number) : 89853L2034
(Date of Event Which Requires Filing of this Statement) :
07/07/2023
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
[ ] Rule 13d?1(b)
[X] Rule 13d?1(c)
[ ] Rule 13d?1(d)
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be ?filed? for the purpose of Section
18 of the Securities Exchange Act of 1934 (?Act?) or otherwise
subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 89853L2034
(1) Names of reporting persons: GSA Capital Partners LLP

(2) Check the appropriate box if a member of a group
(a)
(see instructions)
(b)
(3) SEC use only

(4) Citizenship or place of organization : United Kingdom

Number of shares beneficially owned by each reporting
person with: 4599059

(5) Sole voting power Yes

(6) Shared voting power No

(7) Sole dispositive power Yes

(8) Shared dispositive power No

(9) Aggregate amount beneficially owned by each reporting
person 4599059

(10) Check if the aggregate amount in Row (9) excludes
certain shares (see instructions)

(11) Percent of class represented by amount in Row (9)
1.5%

(12) Type of reporting person (see instructions): IA

Page 2 of 2 Pages
Special Instructions for Complying With Schedule 13G
Under Sections 13(d), 13(g) and 23 of the Securities Exchange
Act of 1934 and the rules and regulations thereunder, the
Commission is authorized to solicit the information required
to be supplied by this schedule by certain security holders of
certain issuers.
Disclosure of the information specified in this schedule is
mandatory. The information will be used for the primary
purpose of determining and disclosing the holdings of certain
beneficial owners of certain equity securities. This statement
will be made a matter of public record. Therefore, any
information given will be available for inspection by any
member of the public.
Because of the public nature of the information, the
Commission can use it for a variety of purposes, including
referral to other governmental authorities or securities self-
regulatory organizations for investigatory purposes or in
connection with litigation involving the Federal securities
laws or other civil, criminal or regulatory statutes or
provisions.
Failure to disclose the information requested by this schedule
may result in civil or criminal action against the persons
involved for violation of the Federal securities laws and
rules promulgated thereunder.
Instructions.
A. Statements filed pursuant to Rule 13d?1(b) containing the
information required by this schedule shall be filed not later
than February 14 following the calendar year covered by the
statement or within the time specified in Rules 13d?1(b)(2)
and 13d?2(c). Statements filed pursuant to Rule 13d?1(d) shall
be filed within the time specified in Rules 13d?1(c), 13d?2(b)
and 13d?2(d). Statements filed pursuant to Rule 13d?1(c) shall
be filed not later than February 14 following the calendar
year covered by the statement pursuant to Rules 13d?1(d) and
13d?2(b).
B. Information contained in a form which is required to be
filed by rules under section 13(f) (15 U.S.C. 78m(f)) for the
same calendar year as that covered by a statement on this
schedule may be incorporated by reference in response to any
of the items of this schedule. If such information is
incorporated by reference in this schedule, copies of the
relevant pages of such form shall be filed as an exhibit to
this schedule.
C. The item numbers and captions of the items shall be
included but the text of the items is to be omitted. The
answers to the items shall be so prepared as to indicate
clearly the coverage of the items without referring to the
text of the items. Answer every item. If an item is
inapplicable or the answer is in the negative, so state.
Item 1(a) Name of issuer: T2 Biosystems Ord
Item 1(b) Address of issuer's principal executive offices: 101
Hartwell Avenue, Lexington, MA, 02421, United States
2(a) Name of person filing: GSA Capital Partners LLP
2(b) Address or principal business office or, if none,
residence: 5 Stratton Street, London, United Kingdom
2(c) Citizenship: UK
2(d) Title of class of securities: Common Stock
2(e) CUSIP No: 89853L203
Item 3. If this statement is filed pursuant to 240.13d?1(b)
or 240.13d?2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the
Act (15 U.S.C. 78o);
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15
U.S.C. 78c);
(c) [ ] Insurance company as defined in section 3(a)(19) of
the Act (15 U.S.C. 78c);
(d) [ ] Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C 80a?8);
(e) [ ] An investment adviser in accordance with 240.13d?
1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in
accordance with 240.13d?1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in
accordance with 240.13d?1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of
the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of
an investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a?3);
(j) [ ] A non-U.S. institution in accordance with 240.13d?
1(b)(1)(ii)(J);
(k) [ ] Group, in accordance with 240.13d?1(b)(1)(ii)(K). If
filing as a non-U.S. institution in accordance with 240.13d?
1(b)(1)(ii)(J), please specify the type of institution:
________
Item 4. Ownership
Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer
identified in Item 1.
(a) Amount beneficially owned: 4599059
(b) Percent of class: 1.5%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 4599059.
(ii) Shared power to vote or to direct the vote 0.
(iii) Sole power to dispose or to direct the disposition of
4599059.
(iv) Shared power to dispose or to direct the disposition of
0.
Instruction. For computations regarding securities which
represent a right to acquire an underlying security see
240.13d?3(d)(1).
Item 5. Ownership of 5 Percent or Less of a Class. If this
statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the
beneficial owner of more than 5 percent of the class of
securities, check the following [ ].
Instruction. Dissolution of a group requires a response to
this item.
Item 6. Ownership of More than 5 Percent on Behalf of Another
Person. If any other person is known to have the right to
receive or the power to direct the receipt of dividends from,
or the proceeds from the sale of, such securities, a statement
to that effect should be included in response to this item
and, if such interest relates to more than 5 percent of the
class, such person should be identified. A listing of the
shareholders of an investment company registered under the
Investment Company Act of 1940 or the beneficiaries of
employee benefit plan, pension fund or endowment fund is not
required.
Item 7. Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported on by the Parent
Holding Company or Control Person. If a parent holding company
or control person has filed this schedule pursuant to Rule
13d?1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an
exhibit stating the identity and the Item 3 classification of
the relevant subsidiary. If a parent holding company or
control person has filed this schedule pursuant to Rule 13d?
1(c) or Rule 13d?1(d), attach an exhibit stating the
identification of the relevant subsidiary.
Item 8. Identification and Classification of Members of the
Group
If a group has filed this schedule pursuant to 240.13d?
1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an
exhibit stating the identity and Item 3 classification of each
member of the group. If a group has filed this schedule
pursuant to Rule 13d?1(c) or Rule 13d?1(d), attach an exhibit
stating the identity of each member of the group.
Item 9. Notice of Dissolution of Group. Notice of dissolution
of a group may be furnished as an exhibit stating the date of
the dissolution and that all further filings with respect to
transactions in the security reported on will be filed, if
required, by members of the group, in their individual
capacity. See Item 5.
Item 10. Certifications
(a) The following certification shall be included if the
statement is filed pursuant to 240.13d?1(b):
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and
are held in the ordinary course of business and were not
acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in
connection with or as a participant in any transaction having
that purpose or effect, other than activities solely in
connection with a nomination under 240.14a?11.
(b) The following certification shall be included if the
statement is filed pursuant to 240.13d?1(b)(1)(ii)(J), or if
the statement is filed pursuant to 240.13d?1(b)(1)(ii)(K)
and a member of the group is a non-U.S. institution eligible
to file pursuant to 240.13d?1(b)(1)(ii)(J):
By signing below I certify that, to the best of my knowledge
and belief, the foreign regulatory scheme applicable to
[insert particular category of institutional investor] is
substantially comparable to the regulatory scheme applicable
to the functionally equivalent U.S. institution(s). I also
undertake to furnish to the Commission staff, upon request,
information that would otherwise be disclosed in a Schedule
13D.
(c) The following certification shall be included if the
statement is filed pursuant to 240.13d?1(c):
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired
and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the
securities and were not acquired and are not held in
connection with or as a participant in any transaction having
that purpose or effect, other than activities solely in
connection with a nomination under 240.14a?11.
Signature. After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth
in this statement is true, complete and correct.
Dated: 07/28/2023
Signature.
Timothy Kuschill
Name/Title.
General Counsel and Chief Compliance Officer
The original statement shall be signed by each person on whose
behalf the statement is filed or his authorized
representative. If the statement is signed on behalf of a
person by his authorized representative other than an
executive officer or general partner of the filing person,
evidence of the representative's authority to sign on behalf
of such person shall be filed with the statement, Provided,
however, That a power of attorney for this purpose which is
already on file with the Commission may be incorporated by
reference. The name and any title of each person who signs the
statement shall be typed or printed beneath his signature.